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THE PURPOSE OF MY REVIEW IS TO PRESENT THEcurrent knowledge of the impact of the sys-temic inflammatory response on morbidity
following cardiac surgery in children. In the first
section, I describe the general principles of the sys-
temic inflammatory response; in the second I con-
sider the impact of cardiac surgery on the systemic
inflammatory response. In the third section, I pres-
ent examples illustrating the relevance of the systemic
inflammatory response for postoperative morbidity
in children. In the fourth section, I review therapeu-
tic strategies to reduce the inflammatory response to
cardiac surgery, and hence postoperative morbidity.
Finally, in the last section, I discuss the influence of
the preoperative condition on the systemic inflam-
matory reaction to cardiac surgery.
The systemic inflammatory response: 
general principles
Systemic inflammation is the non-specific physio-
logical response to a large variety of stimuluses. The
systemic inflammatory response caused by bacterial
or viral infections is the classical example for this.
Systemic inflammation, however, is also elicited by
non-infectious stimuluses. Ischemia and re-perfusion,
trauma, endotoxaemia, and virtually all situations
allowing contact between blood components of an
individual and foreign surfaces are inflammatory
stimuluses.
Initiation and termination of the systemic
inflammatory response
The blood, the liver and the brain are probably the
most important organs controlling initiation and ter-
mination of the systemic inflammatory reaction.1,2
The complement system is involved early in the
complex process of inflammation. Like the systems
underscoring coagulation, contact with plasma, and
fibrinolysis, with which it has numerous interac-
tions, it is activated in the fashion of a cascade.
The complement system may be activated by one
of two pathways, the classical and the alternative, or
by both. The classical pathway is mainly activated by
antigen-antibody complexes, whereas the alternative
pathway is activated by polysaccharides and poly-
mers, such as those found in the cell membrane of
microorganisms or those utilised for the fabrication
of medical artificial surfaces. The activation of either
pathway leads to the formation of C3-convertase,
which activates C3, a key protein of the terminal
sequence of the complement system. The split 
products of this activation are C3a and C3b. C3a is a
potent anaphylatoxin. C3b is part of the C3-convertase
of the alternative pathway, and of C5-convertase,
which is common to both pathways. C5-convertase
activates C5, the split products of which are C5a and
C5b. C5a is the most potent anaphylatoxin. C5b, by
binding the complement proteins C6 to C9 forms the
terminal complex, also called the membrane attack
complex.3 The process of activation of complement
through either pathway, leading to the formation of
the membrane attack complex, is shown in Figure 1.
The biologically active peptides released into the
circulation (Table 1) increase vascular permeability,
cause vasoconstriction, and lead to formation of
oedema. In addition, they activate leukocytes, stim-
ulate phagocytosis, and cause cytolysis.
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Leukocytes, which are major targets for activated
complement proteins, contribute to sustain systemic
inflammation. Upon stimulation, they release products
of degranulation such as elastase, myeloperoxydase
and histamine, and synthesise new inflammatory medi-
ators, such as cytokines. Beside activated complement
proteins,4 classical stimuluses for expression of cyto-
kine genes are bacterial endotoxin, hypoxia,5,6 and
cytokines themselves.6
Cytokines are small, non-constitutive, peptides
that can be produced by virtually all nucleated cells.
They have important physiological functions, as
Classical pathway


























The complement cascade can be activated throughout either the classical or the alternative pathways. The activation of the classical pathway
begins with the binding of an activator to C1, which is composed of 3 portions C1q, C1r and C1s. C1 activates in turn C2 and C4, which
are split into C2a, C2b and C4a, C4b, respectively. The split products C2a and C4b bind to form the C3-convertase of the classical pathway.
The activation of the alternative pathway probably depends upon cleavage of small amounts of C3 in C3a and C3b. C3b is then available
for binding factor B. Factor D cleaves bound factor B to produce Ba and Bb. The complex C3bBb is the C3-convertase of the alternative path-
way that is stabilised by factor P, also called properdine.
Both C3-convertases cleave C3 into C3a and C3b. By binding an additional C3b, both C3-convertases become C5-convertases. The cleavage of
C5 produces C5a and C5b. C5b bounds C6 and in a stepwise fashion, C7, C8 and C9 are added into the complex to form the so called membrane
attack complex. The main molecules with biological properties are represented in red (anaphylatoxins) and in blue (membrane attack complex).
Table 1. Biological properties of the main components of the complement system.
Main cleavage 
Component Pathway products Main biological properties
C1 Classical Binding to antibodies or other activators; Activation of C4 and C2.
C4 Classical C4a Anaphylatoxin: increase of vascular permeability, vasoconstriction, mast cell 
degranulation with release of histamine.
B Alternative Ba Chemotactic.
D Alternative Activates B.
P Alternative Stabilises C3bBb (C3-convertase).
C3 Terminal C3a Anaphylatoxin: increase of vascular permeability, vasoconstriction, mast cell 
degranulation with release of histamine. C3a is a more potent anaphylatoxin than C4a.
C3b Part of the C3-convertase of the alternative pathway and also of the C5-convertases of 
the classical and the alternative pathway.
C5 Terminal C5a Anaphylatoxin: increase of vascular permeability, vasoconstriction, mast cell 
degranulation with release of histamine. In addition, increases neutrophil mobilisation 
(chemotaxis) and adhesion. C5a is a more potent anaphylatoxin than C3a.
C5b Part of the membrane attack complex.
C6, C7, C8, C9 Terminal Part of the membrane attack complex; Cytolysis.
C1-inhibitor Control system Inhibitor of C1.
Nomenclature: The proteins of the classical pathway and of the terminal sequence are termed “components” (C ) and are given a number from 1 to 9.
The proteins of the alternative pathway are represented by a letter (B, D, P). The split products are indicated by a lower case letter (i.e. C3a) (3).
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they regulate intercellular interactions and cell
growth. As far as inflammation is concerned, and
based on their biological properties, cytokines can be
divided into pro- and anti-inflammatory groups.7,8
Pro-inflammatory cytokines have biological pro-
perties that relate to the stimulation of leukocytes,
endothelial cells and virtually all parenchymatous cells,
causing them to produce other inflammatory media-
tors, cytotoxicity, and initiation of cell death.7,9 Cell
death, in both its necrotic and apoptotic forms, will be
discussed in detail later. Tumour necrosis factor- and
interleukin-1, are so-called early pro-inflammatory
cytokines because they are immediately up-regulated
in response to an inflammatory stimulus. They initi-
ate systemic inflammation and, because of their pyro-
genic properties, they elicit the febrile response.1,10
Interleukin-6 is another important pro-inflammatory
cytokine, as it is the principal regulator of the acute
phase response.1 It stimulates the intrahepatic syn-
thesis of acute phase proteins, such as C-reactive pro-
tein. This is a central step for the termination of the
systemic inflammatory reaction, since acute phase
proteins possess anti-inflammatory properties.11
The natural anti-inflammatory response to an
injury is mediated by anti-inflammatory cytokines,
such as interleukin-10 and the interleukin-1 recep-
tor antagonist. The appearance of these cytokines in
the circulation is normally delayed compared to that
of pro-inflammatory mediators, from which their
synthesis, in part, depends. Interleukin-6, in later
states of inflammation, also has anti-inflammatory
properties, since it up-regulates interleukin-1ra and
interleukin-10.12,13
Anti-inflammatory cytokines inhibit the synthe-
sis of pro-inflammatory cytokines.14 By activating
the hypothalamo-pituitary-adrenal axis, they stimu-
late release of cortisol, and thence stop the systemic
inflammatory response.2,12 The principal mechanisms
involved in the initiation and termination of the
acute systemic inflammatory response are shown in
Figure 2, whilst Table 2 summarises the biological
properties of the principal cytokines involved in 
systemic inflammation.
Nuclear factor kappa B: the key transcription
factor of many inflammatory genes
Nuclear factor kappa B plays a central role in inflam-
mation, as it is the main transcription factor for
inflammatory mediators, including pro-inflammatory
cytokines such as tumour necrosis factor-, inter-
leukin-1, and interleukin-6, chemokines such as
interleukin-8, inflammatory enzymes such as indu-
cible nitric oxide synthase, inducible cyclooxyge-
nase, 5-lipoxygenase, and phospholipase A2, and
adhesion molecules such as intercellular adhesion
molecule-1, vascular-cell adhesion molecule-1, and
E-selectin.
Nuclear factor kappa B is a heterodimer com-
prising two subunits, p50 and p65. In the normal
state, it is bound to its natural inhibitory protein,
inhibitory kappa B, which prevents it entering the
nucleus.6 Upon stimulation, inhibitory kappa B
becomes phophorylated and degraded. Nuclear 
factor kappa B is then allowed to translocate into the
nucleus, where it regulates the transcription of
inflammatory proteins.6 Since many inflammatory
proteins controlled by Nuclear factor kappa B act as
activators of this transcription factor, there is an
amplifying loop of inflammation (Fig. 3).
The inflammatory damage to tissues 
and organs
The inflammatory damage to tissues involves complex
mechanisms characterised by the activation of leuko-
cytes, platelets, endothelial, and parenchymal cells.15
















Upon inflammatory stimulation, nucleated
cells produce mediators to which belong the
pro-inflammatory cytokines interleukin-1b,
tumor necrosis factor-a and interleukin-6.
These cytokines are responsible for the
development of the systemic inflammatory
reaction. By inducing the acute phase
response in the liver, and the synthesis 
of anti-inflammatory cytokines such as
interleukin-10 and interleukin-1 receptor
antagonist, pro-inflammatory cytokines
limit their own production. Interleukin-10
activates the hypothalamo-pituitary-
adrenocortical axis and leads to release of
cortisol, which in turn contributes to termi-
nate the inflammatory process.
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Table 2. Biological properties of the main pro- and anti-inflammatory cytokines involved in the pathophysiology of inflammation in the
setting of cardiac surgery.
Cytokine Classification Stimuluses Biological properties
Tumor necrosis Pro-inflammatory Endotoxin; Activated Primary (early) mediator of inflammation; Pyrogen; Inductor 
factor-? cytokine complement; Hypoxia; of acute phase reaction; up-regulates complement proteins; 
Other pro-inflammatory Activates nuclear factor kappa B and hereby leads to 
cytokines up-regulation of many inflammatory genes comprising the
inducible nitric oxide synthase; Procoagulant activity; Produces
cytotoxicity and initiates cell death (necrosis and apoptosis);
Leads to vasodilation, increased vascular permeability, interstitial
oedema, micro-infarctions, leukocyte plugging;
Cardiodepressant (reduces systolic and diastolic myocardial
function); Major mediator in septic shock
Interleukin-1 Pro-inflammatory Endotoxin; Activated Primary (early) mediator of inflammation; Pyrogen; Inductor of 
cytokine complement; Hypoxia; acute phase reaction; up-regulates complement proteins; 
Other pro-inflammatory Activates nuclear factor kappa B and hereby leads to 
cytokines up-regulation of many inflammatory genes comprising the
inducible nitric oxide synthase; Procoagulant activity;
Cardiodepressant; Pyrogenic; Acts synergistically with tumor
necrosis factor-
Interleukin-6 Pro- and also Pro-inflammatory Later mediator of inflammation; Major regulator of the acute 
anti-inflammatory cytokines; Hypoxia. phase response; Stimulates the intrahepatic synthesis of acute 
cytokine phase proteins such as C-reactive protein
Anti-inflammatory properties at later stage of inflammation
by up-regulation of Interleukin-1 receptor antagonist and
Interleukin-10
Interleukin-8 Pro-inflammatory Pro-inflammatory Later mediator of inflammation; Chemokine (leukocyte 
cytokine cytokines; chemotactic factor); Regulates leukocyte recruitment and 
Hypoxia-hyperoxia increases leukocyte-endothelium interactions
Interleukin-10 Anti-inflammatory Endotoxin; Tumor Late mediator of inflammation; Macrophage inhibitor; Inhibits
cytokine necrosis factor- and the production of pro-inflammatory cytokines and chemokines 
other pro-inflammatory as well as its own production; Promotes the release of 
cytokines Interleukin-1 receptor antagonist; Organ protective
Interleukin-1 Anti-inflammatory Pro-inflammatory Antagonises interleukin-1

















Nuclear factor kappa B is the main transcription factor of inflammatory genes. Under normal conditions, nuclear factor kappa B, a heterodimer con-
sisting of two sub-units, p50 and p65, is bound to its inhibitory protein inhibitory kappa B. Upon stimulation, this inhibitory protein undergoes
phophorylation, and thereby degradation. Nuclear factor kappa B is then allowed to translocate into the nucleus, where it regulates the transcription
of inflammatory genes such as pro-inflammatory cytokines, adhesion molecules, and the inducible nitric oxide synthase. Since the proteins resulting from
the activity of nuclear factor kappa B are in turn its activators, an amplifying loop ensues that may lead to uncontrolled inflammation.
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Independent of the local or systemic character of
inflammation, activated complement proteins, and
pro-inflammatory cytokines, lead to the synthesis 
of adhesion molecules by activating Nuclear factor
kappa B.6 Adhesion molecules act to increase leuko-
cyte-endothelium interactions in a 3-stage process.
First, due to the expression of E-(endothelial) and 
L-(leukocyte)-selectins, leukocytes move slowly on
the endothelium and begin to roll on it. In the sec-
ond phase, integrins such as the complement recep-
tor-3 (CD11b/CD18) expressed on neutrophils lead
to the firm adhesion of the leukocytes by binding
activated adhesion molecules such as intercellular
adhesion molecule-1 on endothelial cells. This step
is related to leukocyte degranulation and respira-
tory burst, and thereby to the release of cytotoxic
enzymes which damage the endothelium and the
surrounding tissues. In the third stage, the activated
neutrophils transmigrate into the interstitial tis-
sues,15,16 where they release radical oxygen species,
nitric oxide, inflammatory enzymes and newly syn-
thesised cytokines, all of which act on parenchymal
cells, leading to damage and death of the cells by
necrosis or apoptosis (Fig. 4).
From the stance of inflammation itself, it is crucial
to differentiate these two different pathways for death
of cells. Necrosis involves the loss of integrity of the
cell membrane, and therefore is associated with the
release of inflammatory products into the intersti-
tium. It contributes to the damage of the neighbour-
ing cells, which will also enter the pathway of death.
Necrosis does not require any energy.17 Apoptosis, in
contrast, is a highly genetically controlled pathway,
also known as programmed cell death. Apoptosis is
characterised by maintenance of the integrity of the
cell membrane, and by shrinkage of the cell, which
will be phagocytosed by macrophages. For this reason,
apoptosis is non-inflammatory and a self-limiting
form of death, which does not cause damage to
neighbouring cells and tissues. Apoptosis requires
energy.17,18
Pro-inflammatory cytokines and organ
dysfunction
Systemic or parenchymatous production of pro-
inflammatory cytokines, such as tumor necrosis 
factor- is related to vasodilation, increased vascu-
lar permeability, interstitial oedema, and micro-
infarctions due to leukocyte plugging. These activities
lead to hypoperfusion of the tissues and loss of the
function of the organ.19–21
As far as the myocardium is concerned, tumor
necrosis factor- acts as a cardiodepressant cytokine.
It leads to disruption in the handling of calcium,
desensitises the myofilaments to calcium, and decreases
-adrenoceptor responsiveness.9 The depression of
cardiac function in response to tumor necrosis factor-
is biphasic. The immediate contractile dysfunction
following administration of tumour necrosis factor-
is mediated by sphingosine, a phospholipid meta-
bolite, while the delayed and sustained systolic and
diastolic dysfunction is the result of the activation of
inducible nitric oxide synthase. This leads to the
production of high, non-physiological, concentra-
tions of nitric oxide.9
The balance between the production of 
pro- and anti-inflammatory cytokines
Natural anti-inflammatory cytokines, such as 
interleukin-10, play a central role in the control of
systemic inflammation. Protection of organs is likely to
depend on the aptitude to produce anti-inflammatory
cytokines in response to inflammatory stress.12 Indeed,
in the setting of sepsis, a higher ratio of the circulating
levels of interleukin-6 to interleukin-10 is a predictor


















The inflammatory damage to tissues is related to
the activation of leukocytes by circulating media-
tors such as activated complement proteins and
pro-inflammatory cytokines. Activated leukocytes
express adhesion molecules (green arrow), which
are necessary to achieve interactions between leuko-
cytes and endothelial cells. This results in a
decrease in the velocity of leukocytes in the blood
vessel, in firm adhesion of leukocytes onto the
endothelium, and finally in transmigration of
leukocytes into the interstitial tissue, where they
release toxic degranulation products, which in turn
are responsible for damage to and death of cells.
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cardiac surgery, a higher ratio between circulating
levels of interleukin-10 and interleukin-6 is associ-
ated with less postoperative morbidity.23 Our own
experimental data clearly indicate that greater pro-
duction of interleukin-10 during cardiac surgery is
associated with protection of the organs.24,25
The potential for the anti-inflammatory cytokine
response is probably multifactorial. Factors influenc-
ing this potential are:
 A genetic predisposition due to the presence 
of different polymorphisms for pro- and anti-
inflammatory cytokines.26
 Gender, as female sexual hormones could modify
the anti-inflammatory response.27
 Preoperative conditions such as heart failure and/or
hypoxaemia which lead to systemic and intra-
myocardial inflammation.28,29
 Drug treatments such as corticosteroids, phospho-
diesterase inhibitors or -agonists, which shift the
cytokine balance toward a net anti-inflammatory
cytokine production.30–32
While an adequate anti-inflammatory reaction is
necessary to control systemic inflammation, the ques-
tion as to whether excessive levels of interleukin-10
after cardiac surgery could harm by initiating immune
paralysis, therefore increasing the risk of postopera-
tive infection, has yet to be answered.33 Indeed, in
patients with severe sepsis or trauma, it has been
shown that an hypo-inflammatory state follows the
early phase of uncontrolled inflammation. This hypo-
inflammatory state is related to deactivation of mono-
cytes, with decreased activation of nuclear factor
kappa B. Although the circulating levels of inter-
leukin-10 do not correlate with the degree of mono-
cytic activation, they still remain elevated up to 10
days after the acute inflammatory event, suggesting
that sustained production of anti-inflammatory cyto-
kine is, at least in part, responsible for the immune
paralysis observed.34,35 This points out the impor-
tance of understanding the exact mechanisms regu-
lating the inflammatory balance, permitting both
the control of the systemic inflammation and main-
tenance of immune competence.
The impact of paediatric cardiac surgery on
the systemic inflammatory reaction
More than twenty years ago, Chenoweth and his
group36 first reported the activation of the com-
plement system during cardiopulmonary bypass in
adults. Two years later, Kirklin37 demonstrated the
positive relationship between activation of comple-
ment and postoperative morbidity in adults and in
children. Since then, great efforts have been made to
define better the mechanisms involved in the sys-
temic inflammatory reaction associated with cardiac
surgery. It is widely accepted today that the contact
between blood and foreign surfaces during cardio-
pulmonary bypass initiates the activation of the alter-
native pathway of the complement system.36–38 At the
end of cardiopulmonary bypass, activation of comple-
ment is enhanced by heparin-protamine complexes
that act on the classical pathway.39
The complement system has many interactions
with the contact system of the plasma, with the coag-
ulation system, and with the system of fibrinolysis.
All of them are activated in the setting of cardiac sur-
gery.40 Together, they contribute to sustain systemic
inflammation. Activated complement proteins influ-
ence leukocytic function by stimulating mobilisa-
tion, adhesion, and degranulation of the leukocytes,
and also synthesis of cytokines.6,41 The principal
mechanisms involved in the pathophysiology of car-























Cardiac operations involving cardiopul-
monary bypass are associated with a sys-
temic inflammatory reaction due, in the
first instance, to the contact between blood
and artificial surfaces, resulting in acti-
vation of the complement system. This is
enhanced by ischemia followed by reperfu-
sion of the organs, and by the activation of
the Hageman system, along with the coagu-
lative and the fibrinolytic cascades. Activated
complement proteins, ischemia, and reperfu-
sion are among others inducers of leukocytic
activation and synthesis of pro-inflammatory
cytokines, which contribute to the synthesis
of anti-inflammatory cytokines.
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Activation of complement
Neonates and young children undergoing cardiac sur-
gery with cardiopulmonary bypass show significant
C3- and C5-conversion,37,42–44 indicating late phase
activation of the complement system up to the termi-
nal membrane attack complex. Significant activation
of complement is observed as early as 10 minutes
after institution of cardiopulmonary bypass, and the
peak value of circulating activated complement 
proteins is observed at the end of cardiopulmonary
bypass.43 By this time, several simultaneous events
have taken place, including the reinstitution of myo-
cardial perfusion, the rewarming of the patient, and
the administration of protamine, all factors that sus-
tain activation of complement.39,45,46
Leukocytic activation
The importance of leukocytic activation in causing
damage to the tissues during cardiac surgery in chil-
dren is underscored by studies showing improved
myocardial function in piglets treated with an 
inhibitor of Complement receptor-3 (CD11b/CD18) 
up-regulation on leukocytes.47 In addition to that,
the magnitude of release of elastase or histamine
from activated leukocytes observed during cardiac
surgery in neonates and children has clearly been
associated with the development of postoperative
complications.43,48
Synthesis of cytokines
Neonates, infants and children undergoing cardiac
operations with cardiopulmonary bypass show sig-
nificant production of pro-inflammatory cytokines,
such as tumor necrosis factor- interleukin-6, and
interleukin-8.49 There is also a significant produc-
tion of interleukin-10,50,51 indicating the potential
for the anti-inflammatory response. Usually, concen-
trations of tumour necrosis factor-, interleukin-6,
and interleukin-8 reach maximal values in the plasma
at the end of cardiopulmonary bypass, while those 
of interleukin-10 are measured either at the end of
cardiopulmonary bypass,52 or later on the first post-
operative day.50 The precise time depends on the
perioperative management, including among others,
pretreatment with corticosteroids,30 and the degree
of hypothermia achieved during cardiopulmonary
bypass.50
Complement anaphylatoxins,41 and endotoxin
released from the gut,53 are thought to be the major
triggers for pro-inflammatory production of cyto-
kines during cardiac surgery in children. Other
mechanisms, such as hypoxia and reoxygenation,54
and operative trauma,55 probably also play an impor-
tant role.
Clinical implications of the systemic
inflammatory reaction related to 
cardiac operations
While a certain degree of inflammation is probably
necessary to stimulate angiogenesis, to permit repair
of tissue and healing of wounds after cardiac surgery,
and to protect the patient from infection during the
stay in hospital, there is no doubt that excessive and
uncontrolled inflammation is harmful, especially in
very young children.43,48
Unfortunately, there is no consensus on the 
adequate definition of the systemic inflammatory
reaction syndrome and inflammation-related com-
plications after cardiac surgery in the children.
Reliable epidemiological data, therefore, are not
available. Nevertheless, postoperative dysfunction of
organs associated with uncontrolled inflammation
has been reported in children, and recognised as a
significant problem carrying a high mortality.43
Endothelial damage and the capillary 
leak syndrome
The capillary leak syndrome is a common feature
after cardiac surgery in children. It is characterised
by shift of fluid into the interstitial space, with the
development of generalised oedema, pleural effu-
sion, and ascites.56 If unrecognised and untreated,
the hypovolemic state leads to hypoperfusion of the
tissues, and damage to organs. Neonates are particu-
larly at risk of developing the capillary leak syn-
drome, because they have increased movement of
fluid across the capillary membrane, leading to rapid
shifts from the intra-vascular to the extra-vascular
space. In addition, they have some degree of lym-
phatic insufficiency.57
In neonates undergoing cardiac surgery, factors
influencing the postoperative development of the
capillary leak syndrome include a preoperative inflam-
matory state, characterised by activation of comple-
ment and leukocytosis, and an enhanced inflammatory
response to cardiac surgery, with increased release of
histamine and tumour necrosis factor-.
The increased capillary permeability produced by
the endothelial damage is the substrate for damage
to organs and their dysfunction, as shown in an
experimental model of cardiac surgery.24 As far as
the myocardium is concerned, a clear association
exists between systemic and intra-parenchymatous
synthesis of tumor necrosis factor- and the degree
of intracellular and interstitial oedema due to the
rupture of the cell membrane.25
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The systemic inflammatory response and
damage to myocardial cells
The association between the production of pro-
inflammatory cytokines and the development of
myocardial cellular damage in neonates has recently
been reported by our group.58 Indeed, while cardiac
surgery with cardiopulmonary bypass causes signifi-
cant production of interleukin-6 and interleukin-8
in all neonates undergoing the arterial switch opera-
tion, those who develop postoperative myocardial
dysfunction have higher circulating levels of pro-
inflammatory cytokines than do those without
myocardial dysfunction. The correlation between
postoperative levels of cytokines and troponin-T
suggest a causative relationship between inflamma-
tion and myocardial cellular damage.
We recently demonstrated this causative relation-
ship in an animal model.25
Transient postoperative arrhythmia
Mediators such as histamine not only have inflam-
matory properties, but also act as potent arrhythmo-
genic substances.59 Histamine is released during
cardiopulmonary bypass from mast cells and circu-
lating basophil leukocytes, both targets for a large
number of inflammatory mediators such as com-
plement anaphylatoxins and cytokines. Histamine
increases sinus rate, produces various degrees of atrio-
ventricular block, and enhances the automaticity of
ectopic pacemakers.60 A large number of experimen-
tal studies have demonstrated that histamine induces
sinus tachycardia, junctional ectopic tachycardia, and
ventricular tachycardia, and that these effects are
mediated through its H2-receptors.
59
Transient postoperative arrhythmias, such as junc-
tional ectopic tachycardia, which classically occur after
cardiac surgery involving cardiopulmonary bypass,
are serious complications of surgery for congenital
cardiac defects.61 Junctional ectopic tachycardia is par-
ticularly poorly tolerated in patients with reduced
diastolic function, as it leads to reduced ventricular
filling, and to the loss of the sequential atrioventri-
cular activity.
We suggested that the development of transient
arrhythmias, mainly junctional ectopic tachycardia,
after cardiac surgery in children could be related to
intraoperative liberation of histamine.48 We also con-
firmed the relationship between systemic inflamma-
tion and the occurrence of accelerated nodal rhythms,
including junctional ectopic tachycardia, after car-
diac surgery. Indeed, in a consecutive cohort of 113
children undergoing cardiac surgery with cardiopul-
monary bypass, concentrations of interleukin-6 were
measured in the blood, and interpreted as a marker of
systemic inflammation. The 33 patients who devel-
oped accelerated nodal rhythms had higher levels 
of interleukin-6 immediately after cardiopulmonary
bypass and 4 hours postoperatively than did the 80
children who did not show this complication (Fig. 6).
Prospective randomised trials should be under-
taken to test the hypothesis that histamine antago-
nists, such as the blockers cimetidine or ranitidine,
the latter showing structural similarity with amio-
darone,62 would be efficient and safe for the preven-
tion of rapid nodal rhythms after cardiac surgery in
children.
Failure of multiple systems of organs
Since inflammatory mediators potentially target all
circulating and parenchymatous cells, an uncon-
trolled systemic inflammatory reaction will manifest
itself clinically as multiple failure of organs, a syn-
drome observed in the setting of sepsis, trauma, and
major surgery.63 Cardiac operations with cardio-
pulmonary bypass are representative of this latter
category.
In a study designed to analyse the relationship
between the systemic inflammatory reaction related
to cardiac surgery and the development of postopera-
tive failure of multiple organs, activation of comple-
ment, and release of leukocyte elastase were higher in
children who developed organ failure than in the 
others.43 Patients with failure of multiple organs all
had acute renal and hepatic failure, in addition to car-
diovascular insufficiency, thrombocytopenia, disorders
of coagulation, and temperatures higher than 39
degrees centigrade. Most of them also had transient


















Plasma concentrations of interleukin-6 measured at the end of cardio-
pulmonary bypass and 4 hours postoperatively in 113 infants 
and children having undergone cardiac surgery. Concentrations of
interleukin-6 are significantly higher in the 33 patients with accel-
erated junctional rhythm (yellow) than in the 80 without this 
complication (white). Results are shown as mean standard error of
the mean; *p  0.05 between patients with or without accelerated
junctional rhythm (Mann-Whitney test).
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arrhythmias such as junctional ectopic tachycardia,
respiratory insufficiency, and neurological morbidity.
In accordance with the high mortality known to be
related to the failure of multiple organs, one-third of
our patients with this syndrome died postoperatively.
Prophylactics and treatment
There is, as yet, no specific treatment of the uncon-
trolled systemic inflammatory response syndrome. 
A modulation of this response, nonetheless, can be
achieved by appropriate pharmacological and tech-
nical strategies during the perioperative manage-
ment. These strategies are aimed at enhancing the
balance in favour of the anti-inflammatory response
to cardiac surgery, either by decreasing the produc-
tion of pro-inflammatory mediators or removing
them from the circulation, or by enhancing the pro-
duction of the anti-inflammatory mediators.
Decreasing the production of pro-
inflammatory mediators
Since the primary force of the systemic inflammatory
reaction elicited by cardiac surgery is activation of
complement,64 it is tempting to inhibit the complex
cascade of events which ensues at its first step. This
can be achieved by nonspecific or specific inhibitiors
of the complement system.
Donors of nitric oxide, such as sodium nitro-
prusside, have been shown experimentally to possess
properties that inhibit complement, probably by
inhibiting C3-conversion.65 In a previous study, we
showed that children given low doses of sodium
nitroprusside, 1 µg/kg body weight/minute, during
cardiopulmonary bypass had lower degrees of activa-
tion of complement during and after cardiac surgery,
and also lower postoperative morbidity, than those
who were not treated in this fashion.65
The inhibitor of C1-esterase controls the early
phase of the activation of the classical pathway of the
complement system, and also inhibits the Hageman
factor, coagulation factor X, and fibrinolysis.41
Although we did not find any difference in the con-
centrations of the inhibitor in neonates with and
without capillary leak syndrome,56 Tassani and collab-
orators reported improved pulmonary function in
patients receiving the inhibitor before the opera-
tion.66 Due to its antifibrinolytic properties, which
could enhance the potential for postoperative throm-
bosis, the inhibitor of C1 esterase should be utilised
with caution in small infants.
The recombinant soluble complement receptor
type 1, which inhibits the binding of complement
fragment C3 to its receptor, might be useful in 
mitigating the systemic inflammatory response after
cardiac surgery.67
Heparin-coated circuits have been shown to increase
biocompatibility by attenuating the activation of
complement and stimulation of neutrophils.68 Few
open trials have suggested that they might improve
output of urine and oxygenation in the early post-
operative period.69 Postoperative morbidity and 
mortality, however, are not significantly reduced.70
Serine protease inhibitors such as aprotinin have
been claimed to decrease the inflammatory response
to cardiac surgery in adults.71 This effect, as yet, has
not been confirmed in children.72
Vitamin C and N-acetylcysteine act as scavengers
of free radicals. As such, they might decrease the neu-
trophil oxidative burst during cardiac surgery.73,74
Removing the inflammatory mediators 
from the circulation
Ultrafiltration, introduced by Elliott 10 years ago,75
has now become standard in the perioperative man-
agement of children undergoing cardiac surgery. In
addition to its beneficial effects in removing fluids,
which are associated with improved hemodynamics,
ultrafiltration is also thought possibly to remove
inflammatory mediators from the circulation.51 Peri-
toneal drainage after cardiac surgery in neonates could
also provide dialysis of pro-inflammatory cytokines.76
Decreasing the production of pro-inflammatory
mediators while increasing that of 
anti-inflammatory proteins
Glucocorticosteroids inhibit the synthesis of all inflam-
matory mediators having nuclear factor kappa B 
as their transcription factor (see above). Basically,
glucocorticosteroids act by binding glucocorticoid
response elements on glucocorticoid-responsive genes,
thereby increasing the transcription of many anti-
inflammatory proteins such as interleukin-10, 
interleukin-1ra, Lipocortin-1, and inhibitory kappa
B.6 This effect is genomic. Glucocorticoids also
repress the expression of many inflammatory genes
by inhibiting nuclear factor kappa B.6 This effect is
non-genomic.
In adults, glucocorticoids administered before
cardiac surgery blunt the production of tumor necro-
sis factor- and interleukin-8, and increase that of
interleukin-10.30 In children, the administration 
of dexamethasone at 1mg/kg body weight reduces
the production of tumour necrosis factor- and
interleukin-6, and produces a substantial improve-
ment in outcome.77
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Moderate hypothermia during cardiopulmonary
bypass has been suggested by us to increase the pro-
duction of interleukin-10 in infants.50 This observa-
tion was confirmed in an animal model of cardiac
surgery, where cooling the circulating blood down to
28 degrees centigrade was associated with increased
production of interleukin-10 in blood and parenchy-
mal cells, and with decreased synthesis of tumour
necrosis factor-.24 This shift of the inflammatory
response toward a net anti-inflammatory reaction
was associated with fewer cells dying, and with
greater protection of organs.24,25
The influence of the preoperative condition
As stated above, the potential to initiate and to con-
trol the systemic inflammatory response depends on
individual factors, in which is included the preoper-
ative condition. During cardiac surgery in children,
preoperative conditions potentially affecting the 
systemic inflammatory response to cardiac surgery,
in addition to preoperative infection, mainly involve
myocardial hypertrophy, myocardial failure, hypox-
aemia, or a combination of these factors.23
Haemodynamic overload, such as intracardiac
left-to-right shunting leading to congestive heart
failure or hypoxaemia, stimulates production of
nuclear factor kappa B, and therefore induces the
pro-inflammatory cytokines.78,79 Circulating levels
of interleukin-6 are abnormally elevated in infants
with hypoxaemia or heart failure scheduled for pri-
mary cardiac surgery, the former having the highest
concentrations that correlate inversely with preoper-
ative arterial saturations of oxygen.23 After the oper-
ation, levels of interleukin-6 remain higher in patients
with preoperative hypoxaemia, indicating a priming
of immune competent cells by hypoxaemia that is
possibly responsible for the enhanced inflammatory
response to cardiac surgery seen in those patients.23
The atrial and the ventricular myocardium of infants
requiring cardiac surgery with cardiopulmonary bypass
also contain substantial amounts of cytokines, which
could well increase intramyocardial inflammation in
response to surgery, and therefore contribute to peri-
operative myocardial damage.58
Summary and outlook
Cardiac surgery involving cardiopulmonary bypass
in children is related to a systemic inflammatory
response that comprises activation of complement,
stimulation and degranulation of leucocytes, synthe-
sis of cytokines, and increased interactions between
the leucocytes and the endothelium. Contact between
blood and foreign surfaces during cardiopulmonary
bypass, and ischemia-reperfusion injury, are probably
the main inductors of this complex reaction of the
organism, primarily acting as a mechanism of home-
ostasis. Due to reasons as yet unclarified, the systemic
inflammatory reaction can become uncontrolled,
and then becomes the direct cause of specific postop-
erative morbidity. Complications, such as the capil-
lary leak syndrome, the multiple organ dysfunction
syndrome, and certain types of transient postopera-
tive arrhythmias, are examples for this in neonates
and young children.
Technical and pharmacological interventions aimed
at modulating, but not completely suppressing, the
systemic inflammatory response occurring during
cardiac surgery are promising in providing substan-
tial protection for the organs.
Besides the further clarification of the pathophys-
iological mechanisms contributing to the systemic
inflammatory response to cardiac surgery, modulation
of the balance between pro- and anti-inflammatory
mediators, and stratification of the risk in our popu-
lation of patients, together with excellent operative
and standard postoperative treatment, are manda-
tory for the achievement of very low postoperative
morbidity.
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